跳转至内容
Merck
CN

B8061

N-丁基-N-(4-羟丁基)亚硝胺

ISOPAC®, ≥90% (GC)

别名:

BBN, N-丁基-N-(4-羟丁基)亚硝胺, N-丁基-N-丁-4-醇亚硝胺, N-丁基-N-亚硝基-4-氨基丁醇

登录 查看组织和合同定价。

选择尺寸


关于此项目

经验公式(希尔记法):
C8H18N2O2
化学文摘社编号:
分子量:
174.24
MDL number:
UNSPSC Code:
12352116
NACRES:
NA.25
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

SMILES string

N(N=O)(CCCCO)CCCC

InChI

1S/C8H18N2O2/c1-2-3-6-10(9-12)7-4-5-8-11/h11H,2-8H2,1H3

InChI key

DIKPQFXYECAYPC-UHFFFAOYSA-N

assay

≥90% (GC)

form

liquid

storage temp.

2-8°C

Quality Level

Application

致癌物 N-丁基-N-(4-羟基丁基)亚硝胺(BBN)用于在动物模型中诱导病原学相关的侵袭性膀胱癌。

Biochem/physiol Actions

致癌物质用于在动物模型中诱导膀胱癌。暴露的结果在组织学上与人膀胱肿瘤发生相当。用于化学预防研究。

Packaging

100 mL 血清瓶封装,配有丁基橡胶塞和铝质撕裂密封。

Preparation Note

将内容物溶解在100mL溶剂中,可得到1%的溶液。

Legal Information

Isopac is a registered trademark of Merck KGaA, Darmstadt, Germany

Disclaimer

通过注入任何相容的溶剂可在不暴露内容物的情况下制备任何所需强度的溶液。

pictograms

Health hazardExclamation mark

signalword

Danger

hcodes

Hazard Classifications

Acute Tox. 4 Oral - Carc. 1B

存储类别

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

wgk

WGK 3

flash_point_f

296.6 °F

flash_point_c

147 °C

ppe

Eyeshields, Faceshields, Gloves, type ABEK (EN14387) respirator filter


历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本?

如果您需要特殊版本,可通过批号或批次号查找具体证书。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Koji Nishizawa et al.
International journal of cancer, 127(5), 1180-1187 (2009-12-30)
We previously reported that the expression of CXC chemokine receptor-4 (CXCR4) was upregulated in invasive bladder cancers and that the small peptide T140 was a highly sensitive antagonist for CXCR4. In this study, we identified that CXCR4 expression was induced
Xiao-Li Xie et al.
Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association, 50(11), 3934-3940 (2012-08-15)
In the present study, effects of L-leucine and L-isoleucine on rat bladder carcinogenesis were investigated using AIN-93G and MF basal diet. In Experiment 1, N-butyl-N-(4-hydroxybutyl)-nitrosamine was used as an initiator of bladder carcinogenesis. In the AIN-93G diet groups, a significantly
Jun Miyazaki et al.
Anticancer research, 31(6), 2065-2071 (2011-07-09)
The present gold standard for bladder cancer is Mycobacterium bovis bacillus Calmette-Guérin (BCG) immunotherapy, but serious side-effects are common. We previously reported that C3H/HeN mice vaccinated with a mixture of MBT-2 cells and artificial BCG, octaarginine-modified liposomes incorporating the cell
Paul-Yann Lin et al.
Toxicology and applied pharmacology, 259(1), 27-37 (2011-12-20)
Epidemiological studies have revealed that exposure to an arsenic-contaminated environment correlates with the incidence of bladder cancer. Bladder cancer is highly recurrent after intravesical therapy, and most of the deaths from this disease are due to invasive metastasis. In our
Nelci Antunes de Moura et al.
Archives of toxicology, 84(2), 165-173 (2009-11-11)
The potential promoting effect of Diuron was investigated in a mouse model of mammary and urinary bladder carcinogenesis induced by 7,12-dimethylbenz(a)anthracene (DMBA) and N-butyl-N-(4-hydroxybutyl)nitrosamine (BBN). Four-week old female Swiss mice were allocated to five groups: Groups G1-G3 received DMBA (5

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持